ArticleAmerican journal of translational research2025
Treatment outcomes and determinants of combined hemodialysis-hemoperfusion therapy in chronic glomerulonephritis.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the effects of combined hemodialysis (HD) and hemoperfusion (HP) on serum parathyroid hormone (PTH), phosphorus (P), and calcium (Ca) levels in patients with chronic glomerulonephritis (CGN).
methodsA retrospective analysis was conducted on 118 CGN patients treated between May 2022 and May 2024. Based on therapeutic regimen, participants were divided into the HP group (n=52) and HD+HP group (n=66). Clinical efficacy, bone metabolism indices (PTH, P, Ca), renal function parameters (24 h urinary protein (24 h Upro), blood urea nitrogen [BUN], serum creatinine [SCr], estimated glomerular filtration rate [eGFR]), inflammatory markers (IL-17, TNF-α, hs-CRP), hemorheology, coagulation/fibrinolysis indices (tissue-type plasminogen activator [t-PA]), serum uremic toxins, adverse events, and 36-Item Short Form Health Survey (SF-36) quality-of-life scores were compared. Logistic regression was applied to identify factors associated with poor therapeutic response.
resultsThe HD+HP group showed a higher total effective rate than the HP group (89.39% vs. 73.08%, P=0.021). Compared with HP alone, HD+HP significantly reduced PTH, P, 24 h Upro, BUN, SCr, inflammatory markers, and uremic toxins, while increasing Ca, eGFR, t-PA, and SF-36 scores (all P<0.05). The incidence of adverse events was comparable between groups (30.30% vs. 26.92%, P=0.687). Multivariate analysis identified disease duration >5 years (OR=4.930, 95% CI: 1.339-18.147, P=0.016) and HP monotherapy (OR=3.069, 95% CI: 1.103-8.539, P=0.032) as independent predictors of poor efficacy.
conclusionCombined HD and HP therapy yields superior therapeutic and biochemical outcomes compared with HP alone in CGN patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.